AACR announces launch of new journal, Cancer Discovery

The American Association for Cancer Research announces the launch of its newest journal, Cancer Discovery, which will publish high-impact, peer-reviewed articles describing major advances in basic and clinical research. Its unique format will feature game-changing research, review articles, perspectives and commentaries, news, and "Research Watch" summaries of important journal articles. Cancer Discovery is a new addition to the AACR's robust publication program.

Cancer Discovery combines the expertise and experience of founding Editors-in-Chief Lewis C. Cantley, Ph.D., and Jos- Baselga, M.D., Ph.D., along with full-time professional editors. Mark W. Landis, Ph.D., has been appointed executive editor.

"Cancer Discovery will make major contributions to the growing body of knowledge and be a touchstone for the diverse professional community in the cancer field," said Cantley.

Baselga added, "Topics will span the spectrum of cancer science and medicine; from the laboratory to the clinic to epidemiologic and prevention studies. This is a vital resource for everyone working on the problem of cancer."

"Facilitating communication and cross-disciplinary interactions in the field by publishing excellent journals is a core mission of the American Association for Cancer Research," said AACR Chief Executive Officer Margaret Foti, Ph.D., M.D. (h.c.). "We are thrilled that Cancer Discovery will provide a new publication outlet that captures the most significant work in the field and inspires thinking that will accelerate the pace of breakthroughs."

Cantley is director of the cancer center and chief of the division of signal transduction at Beth Israel Deaconess Medical Center. He is also professor of systems biology at Harvard Medical School. Cantley's laboratory discovered PI3 Kinase (PI3K) and revealed its role in a pathway that controls cell growth and cell transformation. PI3K is implicated in many cancers as well as in other diseases. As a result, pharmaceutical intervention in the PI3K pathway is being explored.

Baselga is chief of the division of hematology/oncology and associate director of the Massachusetts General Hospital Cancer Center. He is also professor of medicine at Harvard Medical School. Baselga's research focuses on the clinical development of novel, molecular-targeted agents for the therapy of cancer, particularly breast cancer. He conducted the initial clinical trials with the monoclonal antibodies cetuximab and trastuzumab and has been involved in the clinical development of several new agents including pertuzumab and PI3K inhibitors. His main focus in the laboratory and clinic is in the area of novel anti-HER2 agents, in the identification of mechanisms of resistance to anti-HER2 agents.

Landis was previously with Cell Press, most recently as senior editor for the journal Molecular Cell. Landis holds a doctorate in biological chemistry and molecular pharmacology from Harvard University, where his work focused on breast cancer. He has held research and teaching assistantships at Dartmouth College, the University of Massachusetts Medical School and Children's Hospital in Boston.

Cancer Discovery is now receiving manuscripts for consideration for publication, and will publish electronically in April 2011 and in print in July 2011. For more information or to submit a manuscript, please view the following link: http://cancerdiscovery.aacrjournals.org/